Background: Lysophosphatidylcholine (LPC) has been suggested to play a functional role in various diseases, including atherosclerosis, diabetes, and cancer mediated by LPC-specific G-protein-coupled receptors. Initial studies provided evidence for a potential use of LPC as diagnostic maker. However, existing methodologies are of limited value for a systematic evaluation of LPC species concentrations because of complicated, timeconsuming procedures. We describe a methodology based on electrospray ionization tandem mass spectrometry (ESI-MS/MS) applicable for high-throughput LPC quantification. Methods: Crude lipid extracts of EDTA-plasma samples were used for direct flow injection analysis. LPC 13:0 and LPC 19:0 were added as internal standards, and the ESI-MS/MS was operated in the parent-scan mode for m/z 184. Quantification was achieved by standard addition. Data processing was highly automated by use of the mass spectrometer software and self-programmed Excel macros. Results: The calibrators LPC 16:0, LPC 18:0, and LPC 22:0 showed a linear response independent of sample dilution and plasma cholesterol concentration for both internal standards. The within-run imprecision (CV) was 3% for the major and 12% for the minor species, whereas the total imprecision was ϳ12% for the major and 25% for the minor species. The detection limit was <1 mol/L. Conclusion: The developed ESI-MS/MS methodology with an analysis time of 2 min/sample, simple sample preparation, and automated data analysis allows highthroughput quantification of distinct LPC species from
Lysophospholipids are biologically active lipids that are involved in a variety of important processes, including cell proliferation, cell migration, angiogenesis, and inflammation (1 ) . Most of the biological effects of lysophospholipids are mediated by G-protein-coupled receptors (2 ) . On the basis of their chemical structures, different bioactive lysophospholipids can be assigned either to the group of lysoglycerophospholipids, e.g., lysophosphatidic acid and lysophosphatidylcholine (LPC), 1 or the group of lysosphingolipids, e.g., sphingosylphosphorylcholine and sphingosine 1-phosphate. Most of the recent research has been directed toward the biological functions of lysophosphatidic acid and sphingosine 1-phosphate, and a pathophysiologic role for these lysophospholipids has been suggested for various diseases (1) (2) (3) . However, increasing evidence suggests that LPC, a precursor of lysophosphatidic acid, also exerts direct biological effects, especially on immune cells.
LPC is a relevant component of human plasma originating from lecithin-cholesterol acyltransferase, hepatic secretion (4, 5 ) , or action of phospholipase A 2 (6 ) . LPC generated by phospholipase A 2 promotes inflammatory effects such as expression of endothelial cell adhesion molecules, growth factors, chemotaxis, and activation of monocytes/macrophages (6 ) . Recently, two G-proteincoupled receptors with a high affinity for LPC were identified: G2A, which is an immunoregulatory receptor (7 ) , and GPR4, which is a receptor for LPC and sphingosylphosphorylcholine (8 ) . LPC has been suggested to play a functional role in the pathogenesis of various diseases, including atherosclerosis (9 ) , diabetes (10 ) , systemic au-toimmune diseases (11 ) , and cancer. Moreover, plasma (12 ) and ascites (13 ) from ovarian cancer patients had increased LPC concentrations, and plasma samples had altered fatty acid composition compared with healthy controls. Taken together, these data indicate a potential use of LPC as diagnostic marker.
Various methods are used for LPC measurement. The most common involve separation by thin-layer chromatography (TLC) (14, 15 ) or HPLC (16 -18 ) . Studies analyzing LPC fatty acid composition used either TLC separation followed by gas chromatographic analysis (12, 19 ) or HPLC coupled to electrospray ionization mass spectrometry (ESI-MS) (20 ) . Recently, a quantification method for different lysophospholipids was published that uses ESItandem MS (ESI-MS/MS) with prior TLC separation (21 ) . The application of these methodologies in the routine laboratory, however, is limited because they are complicated, time-consuming procedures that are to some extent insensitive, unselective, and imprecise. Here we describe a methodology based on the highly specific and selective ESI-MS/MS that is applicable for high-throughput routine LPC quantification.
Materials and Methods reagents
The methanol and chloroform (Merck) were HPLC grade, and the ammonium acetate (Fluka) was of the highest analytical grade available. LPC calibrators were all 1-acyl-2-hydroxy-sn-glycero-3-phosphocholines (Avati Polar Lipids) and were of Ͼ99% purity.
apparatus
Samples were quantified by direct flow injection analysis. The solvent mixture, 10 mmol/L ammonium acetate in methanol-chloroform (3:1 by volume), was provided at a constant flow of 75 L/min by a Waters Alliance 2790. The triple quadrupole mass spectrometer (Quattro LC; Micromass) was operated with the following settings: capillary voltage, 3.5 kV; cone voltage, 41 V; collision energy, 24 V; collision gas, argon at a pressure of 1.3 10
Ϫ3
Torr. Quantification was achieved by a precursor ion scan of m/z 184 specific for phosphocholine-containing lipids (22 ) . Mass resolution was above unit resolution. Data analysis was performed with MassLynx software, which included the NeoLynx tool (Micromass) for averaging the scans at half peak height of the total ion count. NeoLynx generates centroid peak data from the continuum spectra and allows selection of the intensities of certain peaks. These NeoLynx results were exported to Excel spreadsheets and further processed by self-programmed Excel macros, which sorted the results, calculated the ratios to the internal standards, generated Bligh and Dyer (23 ) . The separated chloroform phase was dried and dissolved in 10 mmol/L ammonium acetate in methanol-chloroform (3:1 by volume), producing a 75-fold dilution corresponding to the initial plasma volume. We injected 20 L of this solution, and data were acquired over 2 min.
lpc quantification by tlc
Plasma lipid extracts were separated by high-performance TLC as described previously (24 ) .
Results fragmentation
The general principles of phospholipid fragmentation were described by Brü gger et al. (22 ) , who demonstrated that a positive-ion mode precursor-ion scan of m/z 184 is specific for phosphocholine-containing phospholipids, i.e., phosphatidylcholine and sphingomyelin. The LPC product-ion spectrum in the positive-ion mode displayed several ions originating from the collision-induced dissociation of the phosphocholine head group, including the most intense peak at m/z 184 (Fig. 1) . For sensitive detection, we tested various solvents and ionization additives and selected a mixture of methanol, containing 10 mmol/L ammonium acetate, and chloroform (3:1 by volume), which gave the best results (data not shown). Additionally, a capillary voltage of 3.5 kV and cone Fig. 2) . The spectra contained no peaks that could not be assigned to distinct LPC species.
quantification
For quantitative analysis, we added LPC 13:0 and LPC 19:0, non-naturally occurring species, as internal standards before lipid extraction to compensate for variations in sample preparation and in the ionization efficiency attributable to matrix components or machine instabilities. For all calculations, we used the ratio of analyte to the internal standards rather than the ion counts. To address a possible chain length dependency of species response, we generated calibration curves by adding LPC 16:0, LPC 18:0, and LPC 22:0. Calibration curves calculated with both LPC 13:0 and LPC 19:0 ( Fig. 3 and Table 1 ) showed a linear response for the added LPC species in the range of concentrations added. The added LPC species displayed a response variation Ͻ25% related to the maximum response (Tables 1 and 2 ). The linearity of the method was further documented by an experiment in which two samples, one with low and the other with high analyte concentrations, were mixed at different ratios. The results (Fig. 4 ) indicated that independent of whether LPC 13:0 or LPC 19:0 was used as internal standard, total LPC concentrations at the different mixture ratios followed a strongly linear relationship. Because ESI is highly affected by matrix components, we tested the influence of dilution of the lipid extract and different plasma cholesterol concentrations on the LPC species response. The calibration curve slopes showed no notable differences at cholesterol concentrations of 2.20 and 6.78 mmol/L or dependence on the dilution of the injected solution at 50-to 400-fold dilutions relative to the extracted plasma volume (Table  2) . A 75-fold dilution of the plasma extract was chosen for further measurements and provided satisfactory ion counts. Concentrations of the LPC species were calculated based on the closest related calibration slope, and the results obtained for both internal standards were similar (Table 1) .
assay performance
The within-run imprecision (CV) of the assay was ϳ3% for the total LPC concentration and the major species and ϳ10 -13% for the minor species (Table 3) . The day-to-day Calibration curves were established by standard addition of LPC 16:0, LPC 18:0, and LPC 22:0 to plasma before lipid extraction, yielding LPC concentrations in a range of 0 -100 mol/L. Regression lines were generated by linear leastsquares fitting. A 75-fold dilution corresponding to the initially extracted plasma volume was used. The corresponding regression line coefficients are shown in Table 1 . CTS, counts.
Clinical Chemistry 48, No. 12, 2002 variation was substantially lower when LPC 13:0 was used as the internal standard compared with LPC 19:0, ϳ12% for the major and 25% for the minor species. To assess the detection limit, an analyte-free plasma sample was essential because the effect of the matrix had to be considered. Because such plasma was not available, we determined the limit of detection by calculating the values for the analyte-free regions of m/z 504, m/z 530, and m/z 560, selected from the mass range of the naturally occurring LPC species. The resulting detection limit was 0.6 -0.8 mol/L for both internal standards, calculated from the mean ϩ 3 SD at the above m/z values measured in 10 aliquots of the same sample.
The ESI could be disturbed by contamination in the ion source; we therefore checked the stability of the calibration curve. The calibration curve slope, linearity, and intercept calculated with LPC 13:0 and LPC 19:0 were not influenced by 250 injections of extracted plasma samples showing the stability of the methodology.
sample stability
Because of the possible generation of LPC species by lecithin-cholesterol acyltransferase or phospholipase A 2 , we assessed the stability of the plasma samples at room temperature (Table 4) . LPC species showed a slow increase at room temperature to a 24% total increase at 4 h. In samples stored 1 day at room temperature, the LPC concentration increased 54%; most the increase was in the saturated species LPC 16:0 and LPC 18:0. In contrast, repeated freeze-thaw cycles had no significant effect on LPC concentration.
comparison with tlc
To compare the developed methodology with the existing TLC methodology, we quantified a selected plasma sample by both ESI-MS/MS and TLC. The total LPC concentration obtained by ESI-MS/MS was 184 mol/L, compared with 213 mol/L for the TLC measurement.
Discussion
Different lipid classes, especially lysophospholipids with their well-established role as signaling molecules, are involved in pathophysiologic processes (1 ) . Several studies have indicated the diagnostic potential of LPC, especially a study by Okita et al. (12 ) , which revealed an altered ratio of LPC 18:2 to LPC 16:0 in the plasma of ovarian cancer patients, suggesting the particular importance of LPC species analysis. However, this study used a two-dimensional TLC separation followed by gas chromatographic fatty acid analysis, which is a laborious procedure and a potential source of error. Similarly, a recently published methodology (21 ) uses TLC separation before ESI-MS/MS analysis. Direct coupling of HPLC separation to ESI-MS could be automated (20 ) , but there are also several disadvantages, such as long run times; elution of analytes as narrow peaks, which permits only a short time for MS analysis; and the required coelution of analyte and internal standard, which is needed for correction of possible matrix interactions and machine instabilities. In general, the existing methodologies involve timeconsuming and laborious sample preparations, separation steps, or are not able to analyze the LPC fatty acid a Slope, intercept, regression coefficient, and S y Խ x correspond to the regression lines displayed in Fig. 3 and are representative of a typical measurement. b IS, internal standard. Fig. 4 . Linearity of LPC determination from two samples at different mixture ratios.
Two samples, one with high and the other with low total LPC concentrations, were mixed at different ratios as indicated. Total LPC was quantified with either LPC 13:0 (F) or LPC 19:0 (E) as internal standard. All determinations were in quadruplicate, and each data point represents the mean Ϯ SD. Regression lines were generated by linear least-squares fitting. The regression coefficients (R 2 ) were 0.993 and 0.995 for LPC 13:0 and LPC 19:0, respectively. composition and therefore are not well suited for routine diagnostic application. A recently reported alternative MS methodology, which quantifies LPC species by matrixassisted laser desorption/ionization time-of-flight MS (25 ) , uses the signal-to-noise ratio to eliminate the need for internal standards. Although the signal-to-noise ratio may not appropriately compensate for a potential loss of sample during sample preparation, this methodology could be an interesting alternative to ESI-MS/MS.
Our proposed methodology, based on the highly sensitive and selective ESI-MS/MS, requires only a one-step lipid extraction for sample preparation, which is monitored by addition of two non-naturally occurring LPC species as internal standards. The resulting crude lipid extracts were dried and analyzed by direct flow injection in an optimized solvent mixture. These internal standards also were required to compensate for the various matrix effects on the ESI attributable to changing lipid composition. To address the possible influence of chain length on the ionization response, different LPC species have to be analyzed. To achieve a calibration with a reasonable effort, we chose three species, LPC 16:0, LPC 18:0, and LPC 22:0, which cover the chain length range of naturally occurring LPC species, for calibration by standard addition. In addition, not all naturally occurring LPC species were commercially available. Calibration curves constructed with LPC 13:0 and LPC 19:0 as internal standards showed a linear response in the measured concentration range (Table 1 and Fig. 3) , and the chain length-dependent response displayed a variation within 25% related to the maximum. These similar responses for LPC 16:0, LPC 18:0, and LPC 22:0 were not in accordance with a study by Xiao et al. (21 ) , who found a 75% decrease in the response for the long-chain species LPC 22:0 and LPC 24:0 from the maximum for LPC 16:0 and LPC 18:0. However, this may be related to differences in the mass spectrometer settings as well as in the ionization matrix. The small response variation observed in our protocol should permit calculation of quantitative values of noncalibrated LPC species by use of the closest related calibration curve slope. Although this calculation might not provide exact values, it should at least allow a close quantitative approximation. Moreover, neither sample dilution nor different cholesterol concentrations as surrogate markers of total a Calibration curves were generated from plasma with different cholesterol concentrations. Regression line coefficients were all Ͼ0.99, and the displayed values show the slope and intercept of the regression line generated by linear least-squares fitting. The calibration line consisted of five different concentrations ranging from 0 to 100 mol/L, and the dilution corresponds to the extracted plasma volume.
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lipid content influenced LPC quantification (Table 2) , and the responses were stable during multiple injections. Our quantitative results showed excellent precision for the major species, with a within-run CV of ϳ3%, whereas the lower precision for the minor species may be attributable to a concentration close to the detection limit. One reason for the lower precision between runs may be different machine conditions. These variations were possibly compensated more accurately by LPC 13:0, which had a lower total variation compared with LPC 19:0. However, for the evaluation of minor species, the ratio to other naturally occurring species may be relevant (12 ) , and this ratio showed a much better day-to-day precision (e.g., the ratio of LPC 22:6 to LPC 18:0 had a CV of 11%). Taken together, the application of LPC 13:0 for the calculation of quantitative results and the use of ratios to other naturally occurring species for relevant minor species provide a assay precision well suited for routine measurements. Additionally, LPC 19:0 added in a constant ratio to LPC 13:0 could be used as an internal quality control to confirm the proper ionization response of each sample.
Direct comparison of the LPC concentration determined by ESI-MS/MS with a TLC method showed a good correlation. Moreover, a study by Croset et al. (19 ) , in which the authors analyzed the fatty acid composition of LDL, HDL, and albumin-bound LPC by TLC and gas chromatography, showed a good correlation of the LPC concentration and species with our data. They found a total LPC concentration in these fractions of 150 mol/L, of which 40% was unsaturated fatty acids (Table 3 ; total, 181 mol/L and 34% unsaturated).
All peaks in the spectra of crude plasma lipid extracts could be assigned to distinct LPC species, demonstrating the high selectivity of the parent scan at m/z 184. The high sensitivity is demonstrated by the small plasma volume (20 L) used for lipid extraction and that an injection volume corresponding to 0.3 L of plasma was sufficient for LPC quantification. In contrast to existing protocols, this assay offers advantages regarding analysis time (2 min/sample), the stability of the measurement, the simple sample preparation, and the detailed information obtained for different LPC species. Additionally, self-programmed Excel macros coupled to the commercial mass spectrometer software enable highly automated data processing. The precision of this methodology and its highthroughput capability thus make it suitable for routine application. The EDTA plasma used for LPC quantification showed a slow but continuous increase in LPC concentrations primarily because of increases in the saturated species LPC 16:0 and LPC 18:0, which may be a result of lecithincholesterol acyltransferase (26 ) or phospholipase A 2 activity (27 ) , both of which could hydrolyze phosphatidylcholine mostly at the unsaturated sn-2-acyl group to generate saturated 1-acyl-LPC.
In summary, LPC has been shown to function as a signaling molecule that binds to the G-protein-coupled receptors G2A (7 ) and GPR4 (8 ) . This may be the functional basis for the role of LPC in various diseases (9 -13 ) . A potential diagnostic use has been implicated for patients with ovarian cancer, who exhibit increased plasma LPC concentrations attributable to increases in the saturated species LPC 16:0 and LPC 18:0 (12 ). In contrast, unsaturated LPC 18:1 and especially LPC 18:2 are decreased in the plasma of ovarian cancer patients, which produces an increased LPC 16:0-to-LPC 18:2 ratio, whereas patients with other cancers, such as leukemia, have decreased plasma LPC. Additionally, increased lysophospholipid concentrations, including LPC, have been detected in ascites of these patients (13 ) . LPC may also play an important role during acute phases because acute-phase HDL contained more LPC compared with control samples (20 ) . Additional support for the importance of the distinct LPC species comes from a study in which the plasma of patients with dementia and cognitive impairment was analyzed: only patients who were cognitively impaired but did not have dementia had decreased LPC 22 :6 concentrations (28 ) . These data indicate a potential use of LPC as a diagnostic marker, although this must be evaluated in further studies involving systematic screening of patient groups with conditions associated with a possible pathophysiologic role of LPC. The described methodology, based on ESI-MS/MS, provides an ideal tool for these investigations.
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